These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10212757)

  • 21. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
    Klastersky J
    Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis.
    Mouton JW; Endtz HP; den Hollander JG; van den Braak N; Verbrugh HA
    J Antimicrob Chemother; 1997 May; 39 Suppl A():75-80. PubMed ID: 9511068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
    Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
    Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro activities of quinupristin/dalfopristin in combination with vancomycin and gatifloxacin against Staphylococcus aureus and Enterococcus faecium clinical isolates].
    Gülden E; Ermertcan S
    Mikrobiyol Bul; 2009 Jan; 43(1):53-60. PubMed ID: 19334380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
    Malathum K; Coque TM; Singh KV; Murray BE
    Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
    Ling TK; Fung KS; Cheng AF
    Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
    Jamjian C; Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1997 Apr; 27(4):129-38. PubMed ID: 9154409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.
    Bozdogan B; Leclercq R
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2720-5. PubMed ID: 10543753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):1-21. PubMed ID: 11977919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial susceptibilities of clinical isolates of vancomycin-resistant enterococci in Taiwan.
    Hsueh PR; Wu JJ; Lu JJ; Teng LJ; Luh KT
    J Formos Med Assoc; 1999 Jan; 98(1):45-8. PubMed ID: 10063273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the in vitro activity of pristinamycin and quinupristin/dalfopristin against Streptococcus pneumoniae.
    Lozniewski A; Lion C; Mory F; Weber M
    Pathol Biol (Paris); 2000 Jun; 48(5):463-6. PubMed ID: 10949841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinupristin/dalfopristin.
    Blondeau JM; Sanche SE
    Expert Opin Pharmacother; 2002 Sep; 3(9):1341-64. PubMed ID: 12186626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci.
    Singh KV; Malathum K; Murray BE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3640-3. PubMed ID: 11709359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.